摘要
Background Atrial fibrillation is the most common cardiac arrhythmia in clinical practice. The study examines the situation of antithrombotic therapy in elderly patients （more than 60 years old） with non-valvular atrial fibrillation （NVAF） and acute coronary syndrome （ACS） / percutaneous coronary intervention （PCI）. Methods This study enrolled 381 elderly patients Emean age （69.95 ± 8.41） years; 289 males, 92 femalesl with NVAF and ACS/PCI between January 2006 and September 2013. According to clinical data, these patients were categorized into 4 groups： triple therapy （TT） group, dual antiplatelet therapy （DAT） group, vitamin K antagonist （VKA） plus single antiplatelet therapy （SAT） group and VKA group. According to score of CHA2DS2-VASc and HAS-BLED, all the patients were divided into 4 combinations. Statistical methods were used to analyze the situation of antithrombotic therapy and potential associations between the different combinations. Results 38 patients （9.97%） received TT and 300 patients （78.74%） received DAT. TT was received in 20 patients with CHA2DS2-VASc ≥2 and HAS-BLED ≥3, and 16 patients with CHA2DS2- VASc≥2 and HAS-BLED 〈 3. Conclusions Elderly patients who suffered NVAF and ACS/PCI were with high risk of stroke and low risk of bleeding. Majority of these patients received DAT instead of TT.
Background Atrial fibrillation is the most common cardiac arrhythmia in clinical practice. The study examines the situation of antithrombotic therapy in elderly patients （more than 60 years old） with non-valvular atrial fibrillation （NVAF） and acute coronary syndrome （ACS） / percutaneous coronary intervention （PCI）. Methods This study enrolled 381 elderly patients Emean age （69.95 ± 8.41） years; 289 males, 92 femalesl with NVAF and ACS/PCI between January 2006 and September 2013. According to clinical data, these patients were categorized into 4 groups： triple therapy （TT） group, dual antiplatelet therapy （DAT） group, vitamin K antagonist （VKA） plus single antiplatelet therapy （SAT） group and VKA group. According to score of CHA2DS2-VASc and HAS-BLED, all the patients were divided into 4 combinations. Statistical methods were used to analyze the situation of antithrombotic therapy and potential associations between the different combinations. Results 38 patients （9.97%） received TT and 300 patients （78.74%） received DAT. TT was received in 20 patients with CHA2DS2-VASc ≥2 and HAS-BLED ≥3, and 16 patients with CHA2DS2- VASc≥2 and HAS-BLED 〈 3. Conclusions Elderly patients who suffered NVAF and ACS/PCI were with high risk of stroke and low risk of bleeding. Majority of these patients received DAT instead of TT.
基金
supported by National Nature Science Foundation of China(No.81370295)
